RFK Jr. Lays Off 10,000 Public Health Workers In Single Morning, Resolving Long-Standing Concern That Federal Government Continued To Practice Public Health

The Filing

WASHINGTON. The Department of Health and Human Services on Tuesday morning eliminated approximately 10,000 positions across the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institutes of Health, and HHS proper, executing the largest single-day reduction in force in the agency's 72-year history through emails delivered before sunrise to employees who arrived at federal buildings to find their badges deactivated.

The cuts, announced as part of a broader "restructuring" undertaken by Health Secretary Robert F. Kennedy Jr., reduced the department's workforce by roughly one quarter and were carried out during the same week in which the agency was tracking an active measles outbreak in West Texas, an expanding H5N1 bird flu situation among American dairy cattle, and a separate cluster of pediatric respiratory infections in three states. Officials with the new leadership confirmed that the timing was coincidental and that public health would, in their stated assessment, be improved by removing roughly one in four people whose job had been to practice it.

Among those laid off were career epidemiologists tracking respiratory illness, FDA reviewers responsible for vaccine safety oversight, NIH grants administrators handling cancer and Alzheimer's research disbursements, and the entire CDC division charged with maternal and child health surveillance. The new leadership clarified that those functions would continue, on paper, under reorganized successor offices that did not yet have staff, leadership, or office space.

Mr. Kennedy, in a video address to surviving employees, characterized the action as overdue, citing what he described as decades of waste, corruption, and bureaucracy at the department he had been confirmed to lead seven weeks earlier. Sources within the administration confirmed that the figure of 10,000 had been determined in advance of any review of which positions performed which functions, and that the criterion for retention had been described internally as a matter of judgment rather than role.

President Trump praised the move at a Mar-a-Lago gala. "Bobby is doing an incredible job. Incredible. People love it. They want their freedom. They want their freedom from the agencies. So we're giving them their freedom from the agencies." Asked separately by a reporter whether public health would suffer, the President said it would not, citing his administration's record on what he called "tremendous health, the best health, the best health you've ever seen."

At press time, surviving HHS staff were attempting to determine which office was now responsible for the bird flu surveillance program, the measles response, and federal infant formula supply oversight, none of whose successor units had yet been announced.

Who Benefits

§Donald J. Trump personally, who delivers a rapid 100-day "smaller government" headline that pleases his donor base and signals to the federal workforce broadly that any agency whose work has displeased the President can be reduced overnight.
§Robert F. Kennedy Jr., who acquires a leaner, less specialized HHS more easily aligned with his stated views on vaccines, fluoride, raw milk, and the pharmaceutical industry, with much of the institutional pushback removed from the chain of command.
§Project 2025 architects at the Heritage Foundation, who watch a specific named blueprint item ("restructure HHS, eliminate redundant programs") execute on schedule and at a scale exceeding the document's recommended cuts.
§The pharmaceutical industry, where individual firms now face thinner FDA review staffing, longer queues for unfavorable comparative-effectiveness research, and a quieter regulatory environment for products the new Secretary is unlikely to publicly criticize.
§The supplement, raw-milk, and alternative-medicine industries, which gain reduced FDA enforcement capacity and a Secretary publicly sympathetic to their products.
§Foreign biosecurity competitors, including the People's Republic of China, which gain relative scientific position any time a U.S. administration unilaterally degrades its own public-health surveillance and biomedical research infrastructure.
§Private hospital systems and insurers, which face reduced federal oversight of pricing, fraud, and Medicare Advantage practices.
§Future administrations seeking to dismantle other federal agencies, which now possess a tested template for executing mass reductions in force in a single morning, before legal or congressional response can organize.

Sourced to the public record · presented without editorial embellishment